MA56445A - Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1 - Google Patents

Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1

Info

Publication number
MA56445A
MA56445A MA056445A MA56445A MA56445A MA 56445 A MA56445 A MA 56445A MA 056445 A MA056445 A MA 056445A MA 56445 A MA56445 A MA 56445A MA 56445 A MA56445 A MA 56445A
Authority
MA
Morocco
Prior art keywords
positive allosteric
derivative used
allosteric modulator
tetrahydroisoquinoline derivative
substituted tetrahydroisoquinoline
Prior art date
Application number
MA056445A
Other languages
English (en)
Other versions
MA56445B1 (fr
Inventor
Anne Valade
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA56445A publication Critical patent/MA56445A/fr
Publication of MA56445B1 publication Critical patent/MA56445B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA56445A 2019-07-01 2020-06-29 Dérivé de tétrahydroisoquinoline substitué en tant que modulateur allostérique positif d1 MA56445B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (fr) 2019-07-01 2020-06-29 Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1
EP20735361.6A EP3993795B1 (fr) 2019-07-01 2020-06-29 Dérivé de tétrahydroisoquinoline substitué en tant que modulateur allostérique positif d1

Publications (2)

Publication Number Publication Date
MA56445A true MA56445A (fr) 2022-05-11
MA56445B1 MA56445B1 (fr) 2026-05-26

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56445A MA56445B1 (fr) 2019-07-01 2020-06-29 Dérivé de tétrahydroisoquinoline substitué en tant que modulateur allostérique positif d1

Country Status (28)

Country Link
US (1) US12358890B2 (fr)
EP (1) EP3993795B1 (fr)
JP (1) JP7618597B2 (fr)
KR (1) KR102949226B1 (fr)
CN (1) CN114008032B (fr)
AR (1) AR119317A1 (fr)
AU (1) AU2020299705B2 (fr)
BR (1) BR112021022379A2 (fr)
CA (1) CA3139622A1 (fr)
CL (1) CL2021002949A1 (fr)
CO (1) CO2021017740A2 (fr)
EC (1) ECSP22007557A (fr)
ES (1) ES3069145T3 (fr)
HR (1) HRP20260599T1 (fr)
IL (1) IL289317B2 (fr)
MA (1) MA56445B1 (fr)
MX (1) MX2021015872A (fr)
MY (1) MY210362A (fr)
PE (1) PE20220373A1 (fr)
PH (1) PH12021552819A1 (fr)
PL (1) PL3993795T3 (fr)
RS (1) RS68243B1 (fr)
SA (1) SA521431274B1 (fr)
SG (1) SG11202112539XA (fr)
TW (1) TWI842923B (fr)
UA (1) UA130613C2 (fr)
WO (1) WO2021001286A1 (fr)
ZA (1) ZA202109194B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (fr) 2018-12-18 2020-06-25 Eli Lilly And Company Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques
EP4200280B1 (fr) 2020-10-07 2024-02-21 Eli Lilly And Company Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520217A (ja) 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EA035544B1 (ru) 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
EP3596060B1 (fr) * 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG Nouveaux composés bicycliques utilisés en tant qu'inhibiteurs d'atx
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
BR112021022379A2 (pt) 2022-03-08
AU2020299705B2 (en) 2026-03-19
US12358890B2 (en) 2025-07-15
CN114008032B (zh) 2023-11-10
AU2020299705A1 (en) 2021-12-09
IL289317B2 (en) 2025-09-01
SA521431274B1 (ar) 2024-01-09
US20220251064A1 (en) 2022-08-11
CO2021017740A2 (es) 2022-01-17
IL289317A (en) 2022-02-01
JP7618597B2 (ja) 2025-01-21
KR20220029687A (ko) 2022-03-08
MX2021015872A (es) 2022-02-03
EP3993795A1 (fr) 2022-05-11
TW202115009A (zh) 2021-04-16
SG11202112539XA (en) 2021-12-30
IL289317B1 (en) 2025-05-01
TWI842923B (zh) 2024-05-21
AR119317A1 (es) 2021-12-09
ZA202109194B (en) 2023-11-29
KR102949226B1 (ko) 2026-04-06
CA3139622A1 (fr) 2021-01-07
PE20220373A1 (es) 2022-03-16
MA56445B1 (fr) 2026-05-26
ECSP22007557A (es) 2022-02-25
PH12021552819A1 (en) 2022-09-28
CL2021002949A1 (es) 2022-07-15
HRP20260599T1 (hr) 2026-06-05
CN114008032A (zh) 2022-02-01
UA130613C2 (uk) 2026-04-01
MY210362A (en) 2025-09-13
PL3993795T3 (pl) 2026-07-20
EP3993795C0 (fr) 2026-04-22
EP3993795B1 (fr) 2026-04-22
WO2021001286A1 (fr) 2021-01-07
ES3069145T3 (en) 2026-06-04
RS68243B1 (en) 2026-07-31
JP2022537994A (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
EP4069212A4 (fr) Inhibiteurs de hif-2 alpha
IL284508A (en) Irreversible inhibitors of menin-mll interaction
IL283128A (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
SI3743406T1 (sl) Modulatorji TMEM16A
IL277778B (en) Bcl6 inhibitors
MA56440A (fr) Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1
MA50245A (fr) Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
MA55909A (fr) Inhibiteurs de cdk
IL283967A (en) Modulators of hsd17b13 expression
IL281492A (en) Modulators of pnpla3 expression
EP3801500A4 (fr) Inhibiteurs de sarm1
EP3878007A4 (fr) Formation de réseaux inclinés
EP4058754A4 (fr) Cartographie hyper-locale de conditions environnementales
EP3980011C0 (fr) Inhibiteurs de sarm1
EP3509594A4 (fr) Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
DK3891145T3 (da) Modulatorer af trex1
PL4004284T3 (pl) Powłoki zawierające hemicelulozę
SMT202400402T1 (it) Composti modulatori gpr52
MA43940A (fr) Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
EP4424087A4 (fr) Priorisation de transmissions de signal de synchronisation de liaison latérale
EP3983360C0 (fr) Décomposition de struvite
EP3931328A4 (fr) Modulateurs de l'expression de malat1
EP3509587A4 (fr) Composés monocycliques utiles comme modulateurs de gpr120
EP3955806A4 (fr) Patch multicapteurs
DK3825469T3 (da) Mørtelapplikator